SANTA CLARA, Calif., Oct. 20 /PRNewswire/ -- Applied Imaging Corp.
(Nasdaq: AICX), the leading worldwide provider of automated scanning and
imaging systems for cancer and prenatal cytogenetics, today announced that it
has expanded its Research Collaboration with Dr. Jahn Nesland, Professor and
Head of the Department of Pathology, The Norwegian Radium Hospital.
The expanded collaboration provides for clinical studies on the detection
of breast carcinoma micrometastases in bone marrow using the Applied Imaging
MDS(TM) (Micrometastasis Detection System), which was introduced to the market
in May 1999. As part of the prior collaboration, pathologists in Dr.
Nesland's laboratory determined that the use of the MDS improved the detection
of breast cancer cells in bone marrow when compared to manual examination.
The results of these studies were presented at the International Society of
Hematotherapy and Graft Engineering (ISHAGE) meeting in Oslo, Norway.
"The Applied Imaging automatic scanner for micrometastasis performs
screening of immunostained cytospins with higher sensitivity than manual
screening. This machine can be a useful tool for automating the detection of
tumor cells in clinical samples," stated Dr. Nesland during his presentation
at the ISHAGE meeting. Micrometastatic breast carcinoma cells in bone marrow
and lymph nodes may be identified by immunohistochemical staining for the
presence of cytokeratin filaments. In the bone marrow studies, the MDS
instrument identified more cytokeratin positive tumor cells when compared to
manual scanning. Dr. Nesland is also working with Applied Imaging and the MDS
system to detect rare micrometastatic cells in lymph nodes.
Currently, the Norwegian Radium Hospital is conducting one of the largest
prospective studies in the world to determine the prognostic value of
micrometastasis detection in bone marrow for the initial staging and diagnosis
of breast cancer patients. This study has enrolled approximately one thousand
women who will be followed over a five year period.
The detection of rare micrometastatic cells has broad applicability to the
approximately 1.2 million new patients who are diagnosed with breast,
prostate, colorectal and gastric carcinomas annually. Automated scanning and
detection provides increased sensitivity and reproducibility when compared to
manual microscopic examination. Applied Imaging intends to form other
collaborations to exploit the enhanced scanning and imaging capability of the
MDS system in the field of cancer diagnosis.
Applied Imaging CEO and Chairman, Dr. Jack Goldstein stated, "The unique
capability of the MDS system to find and genetically characterize cancer cells
provides the cancer clinical laboratory and cancer researcher with the tools
needed to improve the accuracy of methods used to stage and monitor a variety
of cancers." For more information about micrometastasis you can visit our web
site at http://www.micrometastasis.org .
The foregoing statement is a forward-looking statement within the meaning
of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act. Actual results could differ materially from those projected in
the forward-looking statement as a result of a number of factors including the
failure of the Company to successfully develop or commercialize its
micrometastasis or prenatal screening system, lack of regulatory approval, and
other such factors as set forth in the Company's form 10K for the year ended
December 31, 1997 as filed with the Securities and Exchange Commission.
Applied Imaging Corporation, based in Santa Clara, California, develops,
manufactures, and markets automated clinical analysis systems used by
laboratories for cancer and prenatal genetics. The Company markets its
products worldwide and has more than 1600 instruments at 800 customer sites in
over 35 countries. Applied Imaging is a publicly traded company listed on the
Nasdaq Stock Market under the Symbol AICX. For additional information on
Applied Imaging via fax, please dial 1-800-PRO-INFO, (732-544-2850 outside of
the U.S.), code AICX.
SOURCE Applied Imaging Corp.
 back to top
Related links:
http://www.micrometastasis.org
CONTACT:
Mike Braden, Corporate Controller of Applied
Imaging Corp., 408-562-0250, General, Traci McCarty, or
Investors, Janet Nelson, both of The Financial Relations Board,
415-986-1591, for Applied Imaging
|
